Maternal and Neonatal Outcomes of Immune Thrombocytopenia in Pregnancy: A Five‐Year Single‐Center Cross‐Sectional Study

Objectives Immune thrombocytopenia (ITP) during pregnancy presents unique management challenges. This study represents the first analysis of ITP outcomes during pregnancy in Qatar, aiming to assess maternal and neonatal outcomes at a tertiary care center. Methods A 5‐year retrospective study (2018–2022) was conducted at Hamad Medical Corporation, analyzing 81pregnant patients with ITP. Data collection included demographics, hematological parameters, complications, management and treatment responses. Results Among the total cohort, 21 patients had chronic ITP, 47 had pre‐pregnancy ITP, and 34 developed ITP during pregnancy. Median platelet counts were 44 × 10⁹/L at diagnosis, with trimester‐specific counts of 36 × 10⁹/L, 44 × 10⁹/L, and 46.5 × 10⁹/L for the first, second, and third trimesters, respectively. Maternal complications were observed in 19.8% of cases, most commonly premature rupture of membranes (4.9%). Neonatal complications affected 12.4% of cases with preterm births (3.8%) and intrauterine growth restriction (3.8%) being the most frequent. The majority (80%) of pregnancies were uncomplicated. Pregnancy‐onset ITP was associated with a higher complication rate (28.5%) compared to pre‐pregnancy ITP (23.2%). Conclusions While the majority of pregnancies with ITP are uncomplicated, pregnancy‐onset ITP show a higher complication rates compared to pre‐pregnancy ITP. These findings provide valuable insights into the management of ITP during pregnancy within the Middle Eastern population.